Updates in intravesical electromotive drug administration® of mitomycin-C for non-muscle invasive bladder cancer

World Journal of Urology

Volumn 27, Issue 3, 2009, Pages 325-330

  Di Stasi, Savino Mauro ^a   Riedl, Claus ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Landesklinikum Thermenregion ^*  (Austria)

Author keywords

Electromotive drug administration; Intravesical therapy; Mitomycin C; Non muscle invasive bladder cancer

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; MITOMYCIN;

ARTICLE; BLADDER TUMOR; CANCER INVASION; ELECTROCHEMOTHERAPY; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; PATHOLOGY;

ADMINISTRATION, INTRAVESICAL; ANTIBIOTICS, ANTINEOPLASTIC; ELECTROCHEMOTHERAPY; HUMANS; MITOMYCIN; NEOPLASM INVASIVENESS; URINARY BLADDER NEOPLASMS;

EID: 67449089043     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-009-0389-x     Document Type: Article

References (30)

1. Parkin DM (2008) The global burden of urinary bladder cancer. Scand J Urol Nephrol 26:1-9
2. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Böhle A, Palou-Redorta J (2008) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 54:303-314. doi: 10.1016/ j.eururo.2008.04.051
3. Pawinski A, Sylvester R, Kurth KH, Bouffioux C, van der Meijden A, Parmar MK, Bijnens L (1996) A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder Cancer. J Urol 156:1934-1940. doi: 10.1016/S0022-5347(01)65396-5
4. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO (1995) Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 153:1444-1450. doi: 10.1016/S0022-5347(01)67427-5
5. Sylvester RJ, Oosterlinck W, van der Meijden AP (2004) A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: A meta-analysis of published results of randomized clinical trials. J Urol 171:2186-2190. doi: 10.1097/01.ju.0000125486.92260.b2
6. Böhle A, Jocham D, Bock PR (2003) Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: A formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90-95. doi: 10.1016/S0022-5347(05)64043-8
7. Dalton JT, Wientjes MG, Badalament RA, Drago JR, Au JL-S (1991) Pharmacokinetics of intravesical mitomycin C in superficial bladder cancer patients. Cancer Res 51:5144-5152
8. Wientjes MG, Dalton JT, Badalament RA, Drago JR, Au JL-S (1991) Bladder wall penetration of intravesical mitomycin C in dogs. Cancer Res 51:4347-4354
9. Schmittgen TD, Wientjes MG, Badalament RA, Au JL-S (1991) Pharmacodynamics of mitomycin C in cultured human bladder tumors. Cancer Res 51:3849-3856
10. Wientjes MG, Badalament RA, Wang RC, Hassan F, Au JL-S (1993) Penetration of mitomycin C in human bladder. Cancer Res 53:3314-3320
11. Wientjes MG, Badalament RA, Au JL-S (1993) Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C treatment for superficial bladder cancer. Cancer Chemother Pharmacol 32:255-262. doi: 10.1007/BF00686169
12. Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP, Miles BJ, International Mitomycin C Consortium (2001) Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial. J Natl Cancer Inst 93:597-604. doi: 10.1093/jnci/93.8.597
13. Stephen RL, Miotti D, Bettoglio R, Rossi C, Bonezzi C (1994) Electromotive administration of a new morphine formulation: Morphine citrate. Artif Organs 18:461-465. doi: 10.1111/j.1525-1594.1994.tb02233.x
14. Bellantone NH, Rim S, Francoeur ML, Rosadi B (1986) Enhanced percutaneous absorption via iontophoresis. Evaluation of an in vitro system and transport of model compounds. Int J Pharm 30:63-72. doi: 10.1016/0378-5173(86)90136-5
15. Banga AK, Chien YW (1998) Iontophoretic delivery of drugs: Fundamentals, developments and biomedical applications. J Control Release 7:1-24. doi: 10.1016/0168-3659(88)90075-2
16. Prausnitz MR, Bose VG, Langer R, Weaver JC (1993) Electroporation of mammalian skin: A mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci USA 90:10504-10508. doi: 10.1073/pnas.90.22.10504
17. Nightingale ER (1959) Phenomenological theory of ion solvation. Effective radii of hydrated ions. J Phys Chem 63:1381-1387. doi: 10.1021/ j150579a011
18. Di Stasi SM, Vespasiani G, Giannantoni A, Massoud R, Dolci S, Micali F (1997) Electromotive delivery of mitomycin C into human bladder wall. Cancer Res 57:875-880
19. Di Stasi SM, Giannantoni A, Massoud R, Dolci S, Navarra P, Vespasiani G, Stephen RL (1999) Electromotive versus passive diffusion of mitomycin C into human bladder wall: Concentration-depth profiles studies. Cancer Res 59:4912-4918
20. Di Stasi SM, Giannantoni A, Stephen RL, Capelli G, Navarra P, Massoud R, Vespasiani G (2003) Intravesical electromotive mitomycin C versus passive transport mitomycin C for high-risk superficial bladder cancer: a prospective randomized study. J Urol 170:777-782. doi: 10.1097/ 01.ju.0000080568.91703.18
21. Brausi M, Campo B, Pizzocaro G, Rigatti P, Parma A, Mazza G, Vicini A, Stephen RL (1998) Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: A comparative Phase II study. Urology 5:506-509. doi: 10.1016/S0090-4295(97)00625-0
22. Riedl CR, Knoll M, Plas E, Pfluger H (1998) Intravesical electromotive drug administration technique: Preliminary results and side effects. J Urol 159:1851-1856. doi: 10.1016/S0022-5347(01)63174-4
23. Di Stasi SM, Storti L, Giurioli A, Zampa G, Liberati E, Sciarra M, Iorio B, Stephen RL (2008) Carcinoma in situ of the bladder: Long-term results of a randomized prospective study comparing intravesical electromotive mitomycin-C, passive diffusion mitomycin-C and Bacillus Calmette-Guerin. Eur Urol Suppl 7(3):180 abs #439
24. Sockett LJ, Borwell J, Symes A, Parker T, Montgomery BSI, Barber NJ (2008) Electro-motive drug administration (EMDA) of intravesical mitomycin-C in patients with high-risk non-invasive bladder cancer and failure of BCG immunotherapy. BJU Int 101(suppl 5):50 abs #U17
25. Rintala E, Jauhiainen K, Rajala P, Ruutu M, Kaasinen E, Alfthan O (1995) Alternating mitomycin-C and Bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. J Urol 154:2050-2053. doi: 10.1016/S0022-5347(01)66691-6
26. Rintala E, Jauhiainen K, Kaasinen E, Nurmi M, Alfthan O (1996) Alternating mitomycin-C and Bacillus Calmette Guerin instillation prophylaxis for recurrent papillary (stages Ta-T1) superficial bladder cancer. J Urol 156:56-59. doi: 10.1016/S0022-5347(01)65936-6
27. Witjes JA, Caris CT, Mungan NA, Debruyne FM, Witjes WP (1998) Results of a randomised phase 3 trial of sequential intravesical therapy with mitomycin-C and Bacillus Calmette Guerin versus mitomycin-C alone in patients with superficial bladder cancer. J Urol 160:1668-1671. doi: 10.1016/S0022-5347(01)62377-2
28. Kaasinen E, Wijkström H, Malmström PU, Hellsten S, Duchek M, Mestad O, Rintala E, Nordic Urothelial Cancer Group (2003) Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: A Nordic study. Eur Urol 43:637-645
29. Di Stasi SM, Giannantoni A, Giurioli A, Valenti M, Zampa G, Storti L, Attisani F, De Carolis A, Capelli G, Vespasiani G, Stephen RL (2006) Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: A randomised controlled trial. Lancet Oncol 7:43-51. doi: 10.1016/S1470-2045(05)70472-1
30. Di Stasi SM, Storti L, Giurioli A, Brausi M, Capelli G, Zampa G, Stephen RL (2008) Single immediate preoperative instillation of electromotive mintomycin-C plus trasurethral resection versus transurethral resection alone versus transurethral resection plus immediate mitomycin-C for pTa bladder tumors: Long-term results of a prospective randomized trial. J Urol 179(suppl 4):585 abs #1707